Breast Cancer Research Breakthroughs Signal Paradigm Shifts Across Disease Subsets
Maryam Lustberg, MD, MPH, discusses insights regarding other key breast cancer data presented at the 2023 ASCO Annual Meeting, including findings from the phase 3 BWEL trial, updated data from the phase 2 ELAINE-2 trial, and the final overall survival analysis of the phase 3 TROPiCS-02 trial.Source: OncLive
CDK4/6 Inhibitors in Breast Cancer: New Populations, Different Settings
At the American Society of Clinical Oncologyopens in a new tab or window (ASCO) annual meeting, a poster discussion session on metastatic breast cancer entitled "CDK4/6 Inhibitors: New Populations, Different Settings" was presented by Maryam Lustberg, MD, MPH opens in a new tab or window, the chief of breast oncology at the Yale Cancer Center in New Haven, Connecticut. She discussed the results from three posters -- the LEONARDA-1 studyopens in a new tab or window, the PALOMAGE programopens in a new tab or window, and the AURORA Molecular Screening Initiativeopens in a new tab or window.Source: MedPage Today
Don’t Let Breast Cancer Subtype Guide Mastectomy Choice, Doctors Say
The decision to have mastectomy is “complex and layered,” says Mehra Golshan, MD, clinical director of the Center for Breast Cancer at Smilow Cancer Hospital and Yale Cancer Center. It requires a shared decision-making between the patient and the provider, says Golshan, who wasn’t involved in the study. “There are some women who absolutely have to have mastectomy. However, most are eligible for either surgery,” Golshan says.Source: WebMD
Studies Question Role of CDK4/6 Inhibitors in First-Line Advanced Breast Cancer
Upfront CDK4/6 inhibition or second-line use in advanced hormone receptor (HR)-positive/HER2-negative breast cancer led to similar cumulative progression-free survival (PFS) in a large randomized trial.Source: MedPage Today
Yale surgical oncologist shares advanced solutions at breast cancer conference in South Korea
In late April, Tristen Park, assistant professor of surgery and oncologist specializing in breast cancer at the Yale School of Medicine, participated in the Global Breast Cancer Conference (GBCC) in Seoul, South Korea.Source: Yale University
I’m a Breast Cancer Surgeon. Here’s What I Think of the New Screening Guidelines.
When I learned that the U.S. Preventive Services Task Force once again changed its recommendation for when women should begin screening for breast cancer — this time recommending women start at age 40 rather than 50 — I had just finished operating on a 48-year-old African American woman with aggressive breast cancer. My patient had presented to doctors with a painful lump. She didn’t think she needed a mammogram for another two years.Source: The New York Times
New Study Shows Trastuzumab Deruxtecan Improves Survival for Patients with HER2-positive Metastatic Breast Cancer
A new phase III study has demonstrated the efficacy of trastuzumab deruxtecan (Enhertu) in patients with HER2-positive metastatic breast cancer whose cancers were resistant to previous treatment with trastuzumab emtansine. Both trastuzumab deruxtecan and trastuzumab emtansine are antibody-drug conjugates, a relatively new type of drug that delivers chemotherapy directly to the cancer cell, minimizing damage to normal tissues. The study was published in The Lancet on April 19, 2023.